Precision Medicine News and Research

RSS

Researchers explore relationship between emotions and poor prognosis in heart disease

Intense distress and fear of dying, which many people experience when suffering the symptoms of a heart attack, are not only fairly common emotional responses but are also linked to biological changes that occur during the event, according to new research published online today in the European Heart Journal.

2 Jun 2011

Study suggests new therapeutic targets for virally-induced asthma attacks

When children with asthma get the flu, they often land in the hospital gasping for air. Researchers at Children's Hospital Boston have found a previously unknown biological pathway explaining why influenza induces asthma attacks.

30 May 2011

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism Conference, leading arthritis researchers presented important data on Augurex's rheumatoid arthritis biomarker blood test and novel drug target.

30 May 2011

Recombinant partners with U.S. Department of Veterans Affairs in genomic research program

Recombinant Data Corp., a Massachusetts-based healthcare data warehousing and clinical intelligence solutions provider, today announced its continued contributions to innovative IT tools for clinical research, through the company's key role in the U.S. Department of Veterans Affairs' Million Veteran Program (MVP).

27 May 2011

ARCA plans to expand development program for Gencaro in atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it is planning to expand the development of Gencaro, its lead cardiovascular drug candidate, to atrial fibrillation, a disease that affects more than 2.4 million patients in the United States.

27 May 2011

Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer

Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 with or without Faslodex in estrogen receptor (ER)-positive breast cancer patients.

27 May 2011

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

There's a wealth of health information hiding in the human immune system. Accessing it, however, can be very challenging, as the many and complex roles that the immune system plays can mask the critical information that is relevant to addressing specific health issues.

25 May 2011

Exosome Diagnostics announces expansion of scientific advisory board

Exosome Diagnostics, a leading developer of biofluid based molecular diagnostic tests for use in personalised medicine, today announced the appointments of Bob Carter MD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB).

24 May 2011

Variant of obesity gene may increase breast cancer risk

New research aimed to better identify the genetic factors that lead to breast cancer has uncovered a link between the fat mass and obesity associated gene and a higher incidence of breast cancer.

24 May 2011

Berkeley Lab scientists reveal how protein-making machine bends without breaking

It sounds like hype from a late-night infomercial: It can twist and bend without breaking! And wait, there's more: It could someday help you fend off disease!

20 May 2011

MDxHealth reduces first quarter net loss by 17%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011.

18 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

The University of Washington Center for Commercialization and Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, today announced the execution of a licensing agreement between the parties.

18 May 2011

$100,000 needed to analyze '$1,000' genetic data

Advances in technology have almost lifted the curtain on the long-awaited era of the "$1,000 genome" - a time when all the genes that make up a person can be deciphered for about that amount - compared to nearly $1 million a few years ago.

12 May 2011

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that applications for market approval for vemurafenib for the treatment of metastatic melanoma have been submitted to the U.S. Food and Drug Administration and the European Medicines Agency.

11 May 2011

FDA clears Affymetrix's new gene profiling reagents for use in microarray instrument system

Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.

9 May 2011

Research experts to speak at brain tumor educational conference

Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.

5 May 2011

ChipDX identifies gene expression signature in early-stage breast tumors

ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years.

4 May 2011

Caliper first quarter revenue increases 25% to $35.8 million

Caliper Life Sciences, Inc., today reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010.

2 May 2011

Michael Dell shows how information technology can improve efficiency, quality of care today

Michael Dell today shared his insights with healthcare executives on how information technology is being used to improve the efficiency and quality of care today and how IT can support future innovations in prevention, wellness and personalized medicine.

30 Apr 2011

Precision Medicine News and Research

Researchers explore relationship between emotions and poor prognosis in heart disease

Study suggests new therapeutic targets for virally-induced asthma attacks

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

Recombinant partners with U.S. Department of Veterans Affairs in genomic research program

ARCA plans to expand development program for Gencaro in atrial fibrillation

Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

Exosome Diagnostics announces expansion of scientific advisory board

Variant of obesity gene may increase breast cancer risk

Berkeley Lab scientists reveal how protein-making machine bends without breaking

MDxHealth reduces first quarter net loss by 17%

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

$100,000 needed to analyze '$1,000' genetic data

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

FDA clears Affymetrix's new gene profiling reagents for use in microarray instrument system

Research experts to speak at brain tumor educational conference

ChipDX identifies gene expression signature in early-stage breast tumors

Caliper first quarter revenue increases 25% to $35.8 million

Michael Dell shows how information technology can improve efficiency, quality of care today

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News